©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 28, 2015; 21(4): 1222-1233
Published online Jan 28, 2015. doi: 10.3748/wjg.v21.i4.1222
Published online Jan 28, 2015. doi: 10.3748/wjg.v21.i4.1222
Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants
Sevgi Ozden, Zerrin Ozgen, Hazan Ozyurt, Cengiz Gemici, Gokhan Yaprak, Huseyin Tepetam, Radiation Oncology, Dr. Lutfi Kirdar Kartal Training and Research Hospital, 34890 Istanbul, Turkey
Alpaslan Mayadagli, Faculty of Medicine, Bezmialem Vakif University, 34093 Istanbul, Turkey
Author contributions: Ozden S designed and performed the research, analyzed the data; Ozden S, Ozyurt H and Ozgen Z performed drafting the article or revising it critically for important intellectual content; Gemici C, Yaprak G and Tepetam H contributed to the treatment and follow up of patients; Mayadagli A was the director of the department at that time of patients’ treatment and follow up; all authors read and approved the final manuscript.
Correspondence to: Sevgi Ozden, MD, PhD, Radiation Oncology, Dr. Lutfi Kirdar Kartal Training and Research Hospital, Cevizli-Kartal-Istanbul, 34890 Istanbul, Turkey. sevgiozden@gmail.com
Telephone: +90-216-4413900 Fax: +90-216-3520083
Received: May 23, 2014
Peer-review started: May 26, 2014
First decision: July 9, 2014
Revised: August 16, 2014
Accepted: October 15, 2014
Article in press: October 15, 2014
Published online: January 28, 2015
Processing time: 248 Days and 22.4 Hours
Peer-review started: May 26, 2014
First decision: July 9, 2014
Revised: August 16, 2014
Accepted: October 15, 2014
Article in press: October 15, 2014
Published online: January 28, 2015
Processing time: 248 Days and 22.4 Hours
Core Tip
Core tip: This retrospective single centre analysis of survival data in patients with resected gastric carcinoma revealed median 31.9 mo of local recurrence free (LRF) survival, 24.1 mo of distant metastasis free survival and 31.9 mo of overall survival via postoperative adjuvant chemoradiotherapy during follow up from 1998 to 2010. Use of 5-fluorouracil and leucovorin-folinic acid and uracil/tegafur based chemotherapy protocols and the absence of positive surgical margin but not the interval between surgery and radiotherapy had a significant impact on survival times, while the nodal stage was the independent prognostic factor for LRF and overall survival.